MarketCap
Facebook
X
TelegramAnnual report 2025
added 11-25-2025
Becton, Dickinson and Company Revenue 2011-2025 | BDX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Becton, Dickinson and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.8 B | 20.2 B | 19.4 B | 18.9 B | 19.1 B | 16.1 B | 17.3 B | 16 B | 12.1 B | 12.5 B | 10.3 B | 8.45 B | 8.05 B | 7.71 B | 7.83 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.8 B | 7.71 B | 14.4 B |
Quarterly Revenue Becton, Dickinson and Company
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.51 B | 5.27 B | 5.17 B | 4.99 B | 5.04 B | 4.71 B | 4.88 B | 4.82 B | 4.59 B | - | 4.64 B | 4.75 B | 4.72 B | - | 4.89 B | 4.91 B | 5.32 B | 4.78 B | 3.86 B | 5.32 B | 4.22 B | 4.58 B | 4.35 B | 4.22 B | 4.16 B | 4.4 B | 4.28 B | 4.22 B | 3.08 B | 3.17 B | 3.04 B | 2.97 B | 2.92 B | 3.23 B | 3.2 B | 2.92 B | 2.99 B | 3.06 B | 3.12 B | 2.99 B | 2.05 B | 2.2 B | 2.16 B | 2.05 B | 2.02 B | 5.95 B | 2.05 B | 2.02 B | 1.9 B | 5.74 B | 1.98 B | 1.9 B | 1.83 B | 5.6 B | 1.95 B | 1.89 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.95 B | 1.83 B | 3.75 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Baxter International
BAX
|
2.75 B | $ 19.11 | 0.95 % | $ 9.75 B |  USA |
 |
Ekso Bionics Holdings
EKSO
|
17.9 M | $ 5.47 | 3.01 % | $ 110 M | USA |
 |
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | USA |
 |
iRhythm Technologies
IRTC
|
592 M | $ 175.8 | -1.49 % | $ 5.48 B | USA |
 |
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | USA |
 |
Repro Med Systems
KRMD
|
28.5 M | $ 6.48 | -0.61 % | $ 295 M | USA |
 |
Harvard Bioscience
HBIO
|
112 M | $ 0.73 | 0.64 % | $ 31 M | USA |
 |
LeMaitre Vascular
LMAT
|
220 M | $ 84.34 | 0.44 % | $ 1.89 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | USA |
 |
ICU Medical
ICUI
|
2.38 B | $ 146.98 | -0.35 % | $ 3.58 B | USA |
 |
Alcon
ALC
|
9.91 B | $ 80.17 | 0.06 % | $ 40.4 B |  Schweiz |
 |
Merit Medical Systems
MMSI
|
1.36 B | $ 87.39 | -0.27 % | $ 5.09 B | USA |
 |
AtriCure
ATRC
|
465 M | $ 40.55 | 0.02 % | $ 1.9 B | USA |
 |
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M | USA |
 |
electroCore
ECOR
|
16 M | $ 4.86 | 1.25 % | $ 26.8 K | USA |
 |
AngioDynamics
ANGO
|
292 M | $ 13.16 | - | $ 538 M | USA |
 |
The Cooper Companies
COO
|
4.09 B | $ 82.57 | -0.37 % | $ 16.4 B | USA |
 |
Glaukos Corporation
GKOS
|
315 M | $ 116.64 | 0.4 % | $ 5.65 B | USA |
 |
Masimo Corporation
MASI
|
2.09 B | $ 133.28 | -0.44 % | $ 7.1 B | USA |
 |
Haemonetics Corporation
HAE
|
1.36 B | $ 80.01 | -0.44 % | $ 4.03 B | USA |
 |
InfuSystem Holdings
INFU
|
110 M | $ 9.11 | 0.77 % | $ 188 M | USA |
 |
Predictive Oncology
POAI
|
1.62 M | - | - | $ 32.4 M | USA |
 |
Intuitive Surgical
ISRG
|
8.35 B | $ 577.15 | -0.03 % | $ 205 B | USA |
 |
OraSure Technologies
OSUR
|
186 M | $ 2.43 | 2.53 % | $ 181 M | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 2.18 | - | $ 22.2 M |  Israel |
 |
Milestone Scientific
MLSS
|
8.63 M | $ 0.29 | -0.48 % | $ 23.1 M | USA |
 |
Nephros
NEPH
|
14.2 M | $ 5.23 | 12.23 % | $ 54.3 M | USA |
 |
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
2.51 B | $ 22.0 | 0.59 % | $ 3.79 B | USA |
 |
Stereotaxis
STXS
|
26.8 M | $ 2.43 | -0.82 % | $ 196 M | USA |
 |
Pro-Dex
PDEX
|
66.6 M | $ 40.4 | -2.38 % | $ 133 M | USA |
 |
Pulse Biosciences
PLSE
|
700 K | $ 14.86 | 1.92 % | $ 714 M | USA |
 |
ResMed
RMD
|
3.58 B | $ 244.44 | -0.07 % | $ 35.7 B | USA |
 |
Repligen Corporation
RGEN
|
632 M | $ 165.66 | -0.42 % | $ 9.23 M | USA |
 |
BioLife Solutions
BLFS
|
82.3 M | $ 25.41 | -0.2 % | $ 1.17 B | USA |
 |
STAAR Surgical Company
STAA
|
314 M | $ 23.63 | -1.25 % | $ 1.16 B | USA |
 |
STERIS plc
STE
|
5.46 B | $ 255.68 | 0.11 % | $ 25.2 B | USA |
 |
Retractable Technologies
RVP
|
33 M | $ 0.82 | 0.01 % | $ 24.5 M | USA |
 |
Teleflex Incorporated
TFX
|
3.05 B | $ 122.33 | 0.03 % | $ 5.73 B | USA |
 |
Utah Medical Products
UTMD
|
12.3 M | $ 56.29 | -1.14 % | $ 204 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
3.79 B | $ 11.22 | 1.26 % | $ 2.28 B | USA |
 |
West Pharmaceutical Services
WST
|
2.89 B | $ 276.66 | -0.3 % | $ 20.2 B | USA |